Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
August 26, 2025
In the News
Patrick McMahon Weighs in on Genetic Privacy Cases
Foley & Lardner LLP partner Patrick McMahon shared takeaways for employers following recent rulings under Illinois' Genetic Information Privacy Act (GIPA) in the Law360 article, "New Rulings Bolster Plaintiffs In Ill. Genetic Privacy Suits."
August 26, 2025
In the News
Foley Featured in Member Spotlight by Nashville Chamber
Foley & Lardner LLP is featured in a Member Spotlight Q&A by the Nashville Area Chamber of Commerce.
August 26, 2025
In the News
Natasha Allen on AI Investment Due Diligence – 'It's a whole new set of considerations'
Foley & Lardner LLP partner Natasha Allen assessed the growing investment in ethical artificial intelligence systems in the PitchBook article "Allocators add AI to ESG concern."